

Cover Story
FreeGuest Editorial
By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Cancer History ProjectFree
By Alexandria Carolan and Katie Goldberg
Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - Anthony Letai sworn in as 18th NCI director
- Bhattacharya: New grant review criterion is “not political”
- Population-based cancer surveillance is a national treasure at risk